[FOR RELEASE October 11, 2016 China Biologic Receives CFDA Clinical Trial Approval for Human Antithrombin III BEIJING, China – October 11, 2016 – ATIII is intended to treat hereditary and acquired ATIII deficiency in connection with surgical or obstetrical procedures, and to treat thromboembolism. No]
[FOR RELEASE October 11, 2016 China Biologic Receives CFDA Clinical Trial Approval for Human Antithrombin III BEIJING, China – October 11, 2016 – ATIII is intended to treat hereditary and acquired ATIII deficiency in connection with surgical or obstetrical procedures, and to treat thromboembolism. No]
[China Biologic Receives CFDA Clinical Trial Approval for Human Coagulation Factor IX BEIJING, Sept. 19, 2016 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that Shandong Taibang Biological Products Co. Ltd., the Company's majority-owned subsidiary, recently obtained approval from the China Food and Drug] []
[China Biologic Receives CFDA Clinical Trial Approval for Human Coagulation Factor IX BEIJING, Sept. 19, 2016 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that Shandong Taibang Biological Products Co. Ltd., the Company's majority-owned subsidiary, recently obtained approval from the China Food and Drug] []
[China Biologic Announces Change to Board of Directors BEIJING, Aug. 15, 2016 /PRNewswire/ – Entities affiliated with Warburg Pincus have been shareholders of the Company since 2010, and Warburg Pincus entities have reduced their holdings in the Company over the last year in the ordinary course of their investing business, and now hold less than 0.1% of the Company’s outstanding] []
[China Biologic Announces Change to Board of Directors BEIJING, Aug. 15, 2016 /PRNewswire/ – Entities affiliated with Warburg Pincus have been shareholders of the Company since 2010, and Warburg Pincus entities have reduced their holdings in the Company over the last year in the ordinary course of their investing business, and now hold less than 0.1% of the Company’s outstanding] []
[FOR RELEASE August 4, 2016 China Biologic Reports Financial Results for the Second Quarter of 2016 --2Q16 Total Sales Up 23.4% with Non-GAAP Net Income Up 31.3% YoY in RMB terms, or Up 15.5% YoY to $91.4 Million and 23.1% YoY to $35.2 Million in USD terms, respectively --1H16 Total Sales Up 26.2% with Non-GAAP Net Income Up 30.6% YoY] []
[FOR RELEASE August 4, 2016 China Biologic Reports Financial Results for the Second Quarter of 2016 --2Q16 Total Sales Up 23.4% with Non-GAAP Net Income Up 31.3% YoY in RMB terms, or Up 15.5% YoY to $91.4 Million and 23.1% YoY to $35.2 Million in USD terms, respectively --1H16 Total Sales Up 26.2% with Non-GAAP Net Income Up 30.6% YoY] []
[China Biologic Products, Inc. 18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China August 4, 2016 VIA EDGAR 100 F Street, N.E. Re: Notice of Disclosure Filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the]
[] [STATE OF DELAWARE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CHINA BIOLOGIC PRODUCTS, INC. Corporation China Biologic Products, Inc., a corporation organized and existing under the laws of the State of Delaware (the “ The name of the Corporation is China Biologic Products, Inc. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State] [Settlement Agreement This settlement agreement (this “Agreement”) was entered into by and among the following parties (the “Parties,” and each a “Party”) in Yunyan District, Guiyang City, China on July 31, 2016: Party A: Guizhou Taibang Biological Products Co., Ltd. Party B: Guiyang Dalin Biologic Technologies Co., Ltd. Party C: Guizhou Jie’an Company Party D: Shenzhen Yigong Shengda Technology Co.,] [Guarantee Agreement This Guarantee Agreement (this “Agreement”) was entered into by the following parties (the “Parties,” and each a “Party”) at No.808 Meeting Room No. 3 Office Building of Guizhou Province Government in Guiyang City, China on July 31, 2016: Party A: Guizhou Taibang Biological Products Co., Ltd. (“Guizhou Taibang”) Party B: Guiyang Dalin Biologic Technologies Co., Ltd. (“Guiyang Dalin”)] [CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Agreement”) is entered into as of this July 1, 2016 (the “Effective Date”) by and between CHINA BIOLOGIC PRODUCTS, INC., a Delaware corporation (the “Company”) and Mr. Hui (David) Li (hereinafter referred to as the “Consultant”). WHEREAS, NOW, THEREFORE, Senior Strategic and Investment Consulting Agreement 1. provided however Term 2. Compensation 3. (c) Consultant] [Second Amended and Restated Employment Agreement Agreement Company Executive This Second Amended and Restated Employment Agreement (this “ 2012 Agreement WHEREAS, the Company and the Executive entered into an employment agreement dated as of May 11, 2012 (the “ 2014 Agreement WHEREAS, the Company and the Executive entered into a renewal employment agreement dated as of May 11, 2014 (the] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang (Principal Financial and Accounting Officer) Chief Financial Officer]
